CoChat

High response rate to PD-1 blockade in desmoplastic melanomas

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Desmoplastic melanoma is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, and is highly associated with ultraviolet light-induced DNA damage. We analysed sixty patients with advanced desmoplastic melanoma who had been treated with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1). Objective tumour responses were observed in forty-two of the sixty patients (70%; 95% confidence interval 57-81%), including nineteen patients (32%) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF1 mutations (fourteen out of seventeen cases) in these tumours. Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were highly associated with increased CD8 density and PD-L1 expression in the tumour invasive margin. Therefore, patients with advanced desmoplastic melanoma derive substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy, even though desmoplastic melanoma is defined by its dense desmoplastic fibrous stroma. The benefit is likely to result from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature25187

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 338

Metadata

Authors
Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., Gherardini, P. F., Chmielowski, B., Wang, X., Shintaku, I. P., Wei, C., Sosman, J. A., Joseph, R. W., Postow, M. A., Carlino, M. S., Hwu, W.-J., Scolyer, R. A., Messina, J., Cochran, A. J., Long, G. V., & Ribas, A.
Affiliations
  • University of California, Los Angeles (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of California, San Francisco (US)
  • Vanderbilt University (US)
  • Melanoma Institute Australia (AU)
  • Memorial Sloan Kettering Cancer Center (US)
  • Georgetown Lombardi Comprehensive Cancer Center (US)
  • Parker Institute for Cancer Immunotherapy (US)
  • Mayo Clinic (US)
  • The University of Sydney (AU)
  • University of South Florida (US)
Corresponding author
Ribas, Antoni
Venue
Nature
Published
2018-01
Volume
553
Issue
7688
Pages
347-350
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2784063247
Cited by
338
References
31
Citations by year
2026: 10 · 2025: 25 · 2024: 36 · 2023: 47 · 2022: 37 · 2021: 52 · 2020: 48 · 2019: 54 · 2018: 28
FWCI
17.10
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
Funders
  • American Society of Clinical Oncology
  • Moffitt Cancer Center (P30CA076292, CA076292)
  • Tower Cancer Research Foundation
  • Hope Foundation
  • Parker Institute for Cancer Immunotherapy (R35 CA197633)
  • University of Sydney
  • National Institutes of Health (CA197633)
  • National Health and Medical Research Council
  • National Cancer Institute (CA197633, P01CA168585, CA076292, CA168585, P50CA168536, K12CA090625, P30CA008748, P30CA076292, R35CA197633)
  • National Institute of General Medical Sciences (T32GM008042)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
desmoplastic melanoma, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, immunotherapy response, CD8+ T cell infiltration, PD-L1 expression, tumor mutational burden, NF1 mutation, tumor stroma, UV-induced DNA damage, tumor-infiltrating immune cells
MeSH terms
Biopsy, Humans, Immunotherapy, Melanoma, Mutation, Retrospective Studies, CD8-Positive T-Lymphocytes, Neurofibromin 1, Cell Cycle Checkpoints, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High response rate to PD-1 blockade in desmoplastic melanomas. https://app.cochat.ai/papers/10.1038/nature25187
The paper
Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., Gherardini, P. F., Chmielowski, B., Wang, X., Shintaku, I. P., Wei, C., Sosman, J. A., Joseph, R. W., Postow, M. A., Carlino, M. S., . . . Ribas, A. (2018). High response rate to PD-1 blockade in desmoplastic melanomas. Nature. https://doi.org/10.1038/nature25187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.